Articles by Terence Friedlander, MD
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape.
The panel shares their hopes for the future of bladder cancer treatment.
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
The panel shares treatment sequencing decisions based on a few patient scenarios.
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
The panel shares lessons learned from the phase THOR study.
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
The panel discusses the CheckMate 901 study results.
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.